Pharmacological interventions may be considered for persistent symptoms, but only under medical supervision
Any patient who has a new onset of erectile dysfunction or symptoms of low testosterone should be evaluated, says Dr
Consistent with these findings, an updated meta-analysis of thirteen phase 2 and phase 3 RCTs (n = 1,811 participants) showed that GLP-1RAs, especially semaglutide 2.4 mg weekly, significantly reduce hepatic fat content, promote MASH resolution, and improve liver fibrosis in patients with MASH, regardless of T2DM status (Mantovani et al., 2025[42])
When patients experience persistent gastrointestinal symptoms, general malaise and reduced well-being can diminish sexual desire, though this represents a secondary rather than direct pharmacological effect